Yuhan inks $81 mn contract with U.S. Gilead to supply HIV …
WEB2 days ago · South Korean pharmaceutical company Yuhan Corp. announced on Friday that it has signed a contract with U.S. biopharmaceutical company Gilead Sciences Inc. to supply raw materials for human immunodeficiency virus (HIV) treatments. The contract is worth 107.6 billion won ($80.8 million), which is 5.79 percent of Yuhan’s sales in 2023. ...
Yuhan inks $80.9M deal with Gilead Sciences for HIV drug …
WEB2 days ago · Yuhan has secured an $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the treatment of human immunodeficiency virus (HIV), the Korean drugmaker announced in an electronic disclosure on Friday. The contract runs through Sept. 30, 2025, according to the regulatory filing. Yuhan eyes next Leclaza ...
Gilead taps Korea's Yuhan to supply HIV drug ingredients in …
WEB2 days ago · The deal amount represents 5.8% of Yuhan’s latest yearly sales of 1.85 trillion Korean won ($1.4 billion), according to a filing. Yuhan co-promotes several Gilead HIV drugs, including the ...
| YUHAN
WEBSustainability Report Social Responsibility Global Citizenship Yuhan Foundation Yuhan School. About Yuhan. Corporate Overview CEO’s Greeting Vision History Affiliates Location. Contact Us. Contact Us. Custom Synthesis Service; Finished Products; Supply Chain Management; Dr.Ilhan New 74, NORYANGJIN-RO, DONGJAK-GU, SEOUL, KOREA. Tel : +82-2-828 ...
Yuhan, Janssen halt next-gen cancer drug collaboration - The Korea …
WEB2 days ago · South Korean pharmaceutical giant Yuhan announced Friday it has terminated its collaboration with Janssen Biotech on the development of a next-generation targeted anticancer drug, citing the ...
Yuhan - Wikipedia
WEBYuhan Corporation (Korean: 주식회사 유한양행; Hanja: 株式會社 柳韓洋行; RR: Jusik Hoesa Yuhan Yanghaeng) is a South Korean pharmaceutical and chemical company headquartered in Daebang-dong, Dongjak-gu, Seoul. It was established in 1926 by New Il-han and has been listed on the Korea Stock Exchange since 1962.
[INTERVIEW] Yuhan USA is searching for its next promising …
WEBJan 11, 2023 · Yuhan, a Seoul-based biopharmaceutical company best known for its licensing of a novel lung cancer treatment called lazertinib, sold under brand Leclaza, has clinched a deal with Yansen to export the drug and is now looking for its next target.
About Yuhan/Corporate Overview | YUHAN
WEBYuhan has always emphasized research and development as its top corporate priority. The company approaches R&D through innovative, nimble and translational methodologies. This three-fold dynamic allows Yuhan to continue its over-arching commitment to …
Yuhan’s lung cancer treatment lazertinib wins approval - The Korea …
WEBJan 18, 2021 · The title for Korea’s 31st homegrown novel drug goes to Yuhan’s lung cancer treatment, Leclaza. On Monday, the Ministry of Food and Drug Safety announced its approval for the...
About Yuhan/History | YUHAN
WEBYuhan Corporation is recognized as the most respected company in Korea by the Korean Management Association; Received Korean government’s ($100 million USD) Export Tower Award; First in Korean pharmaceutical industry to receive 10th No-Accident certificate
Skip to content